Onkologie. 2009:3(5):285-291

The role of chemotherapy in lung cancer treatment

doc. MUDr. Jana Skřičková CSc1, Lenka Babičková2, Jana ©peldová1
1 Klinika nemocí plicních a tuberkulózy, FN Brno Bohunice
2 Klinika nemocí plicních a TBC, Fakultní nemocnice Brno a LF MU

According to statistics of the year 2005 bronchogenic carcinoma is one of the tumours with the highest incidence and in men the most

common cause of death of malignant tumours. In the time of diagnosis determination more than 50 % of patients have tumours in

advanced stages, when local treatment is not possible. One of the basis medical possibilities of bronchogenic carcinoma treatment is

chemotherapy, that we are deal with in our message.

Keywords: bronchogenic carcinoma, non-small cell lung carcinoma, small cell lung carcinoma, chemotherapy.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skřičková J, Babičková L, ©peldová J. The role of chemotherapy in lung cancer treatment. Onkologie. 2009;3(5):285-291.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z, Vorlíček J, Táborská E, Sedláčková ©, ©mardová J, Tomíąka M. Protinádorová chemoterapie (295-354). In: Adam Z, Vorlíček J, Koptíková J a kol.: Obecná onkologie a podpůrná léčba. Grada Publishing Praha 2003: 788.
    2. Ginsberg RJ. Lung Cancer. BC Decker Hamilton, London, 2002: 175.
    3. Skřičková J a kol.: Bronchogenní karcinom (41-62). In: Adam Z, Vorlíček J, Vaníček J a kol.: Diagnostické a léčebné postupy u maligních chorob. Druhé, aktualizované a doplněné vydání. Grada Publishing Praha 2004: 692.
    4. Travis WD, Colby TV, Corrin B, et al. eds. Histological typing of lung and pleural tumours. WHO international Histological Classification of Tumours, 3rd edn Berlin: Springer, 1999. Go to original source...
    5. Peąek M, et al. Bronchogenní karcinom. Galén, Praha, 2002: 235.
    6. Zatloukal P, Petruľelka L. Karcinom plic. Grada, Praha, 2001: 367.
    7. http://www.svod.cz.
    8. Giroux DJ, Rami-Porta R, Chansky K, et al. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol 2009; 4: 679-683. Go to original source... Go to PubMed...
    9. Kolek V, Grygárková I, Hajdúch M, et al. Neoadjuvantní chemoterapie u hraničně operabilních stadií IIIA nemalobuněčného karcinomu plic kombinací vinorelbin a karboplatina. Následná cílená adjuvantní chemoterapie. Klinická onkologie 2001; 14: 55-58.
    10. Le Chevalier T, Arriagada R, Le Pechoux C, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350: 351-360. Go to original source... Go to PubMed...
    11. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22: 330-363. Go to original source... Go to PubMed...
    12. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a metaanalysis of survival outcomes. Lung Cancer 2005; 47: 69-80. Go to original source... Go to PubMed...
    13. Altuang O, Stewart D, Fossella FV, et al. Many Patients over 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy. J Thorac Oncol. 2007; 2: 141-146. Go to original source... Go to PubMed...
    14. Sirohi B, Ashley S, Bortin A, et al. Early Response to Platinum - Based First - Line Chemotherapy in Non-Small Cell Lung Cancer May Predict Survival. J Thorac Oncol. 2007; 2: 735-740. Go to original source... Go to PubMed...
    15. Scagliotti GV, Parikh P, Pavel J, et al. Phase III Study Comparing Cisplatin Plus Gemicitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patiens with AdvancedStage Non Small-Cell Lung Cancer. J Clin Oncol 2008; 26: 3543-3551. Go to original source... Go to PubMed...
    16. Hanna NH, Shepherd FA, Rosell R. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597. Go to original source... Go to PubMed...
    17. Hirsch FR, Spreafico A, Novello S, et al. The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer. J Thorac Oncol 2008; 3: 1468-1481. Go to original source... Go to PubMed...
    18. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27: 18S (CRA8000). Go to original source...
    19. Tisseo M, Ardizzoni A. Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung Cancer. J Thorac Oncol 2007; 2: 764-772. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.